
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Coverage of our peer-reviewed research in the healthcare and mainstream press.
The Gainesville Sun depicted the stories of patients with Parkinson’s disease and their family members in an article titled “






